Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
$21.34
-$0.05(-0.51%)
At close: 4:00 PM EST
$21.34
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$8.09 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)812.00K
Market Cap
$1.21B
Enterprise Value$922.00M
Total Cash (Recent Filing)$343.19M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
May 14, 2026EPS Estimate
-1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding57,361,260
10 Day Avg. Volume958,491
30 Day Avg. Volume811,995
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue92.20
Enterprise Value/Gross Profit-24.24
Enterprise Value/Ebitda-4.36
Forecast
1Y Price Target
$43.50Price Target Upside103.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.5
Revenue Forecast (FY)$9.38M
Bulls Say, Bears Say
Bulls Say
Commercial DifferentiationAt-home subcutaneous administration, faster B-cell recovery, and favorable pharmacoeconomics could drive patient preference and enable meaningful uptake versus an intravenous competitor.
Financing And RunwaySecured non-dilutive debt financing alongside a substantial cash position should extend operational runway and reduce near-term dilution risk, supporting continued clinical development.
Regulatory ApprovalAnalyst views regulatory approval in IgG4-related disease as likely following positive Phase 3 results and a favorable safety profile, which could support a commercial launch.
Bears Say
Competitive RiskA competing cytolytic anti-CD19 antibody with stronger efficacy could erode obexelimab's commercial potential despite its favorable safety and dosing advantages.
Market Perception And ValuationPerception that Phase 3 results were less impressive than a rival and a resultant market selloff that discounted the IgG4 opportunity could limit short-term stock recovery and investor enthusiasm.
Regulatory Uncertainty For MSUncertainty around acceptable regulatory endpoints for relapsing multiple sclerosis creates strategic risk for the BTK inhibitor program until clearer guidance is provided.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $8.09 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.21B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 28 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Mar 16, 2026. The company reported -$4.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$3.539.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.47.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 57,361,260 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$4.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -3.369%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.50 (103.84% Upside)
$43.50 (103.84% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
151.05%
12-Months-Change
Fundamentals
Return on Equity
-156.98%
Trailing 12-Months
Asset Growth
3.70%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$43.50
▲(103.84% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---